scholarly journals Nonleukemic Granulocytic Sarcoma of Knee: A Case Report

2010 ◽  
Vol 2010 ◽  
pp. 1-3 ◽  
Author(s):  
Ibrahim Elghissassi ◽  
Hanane Inrhaoun ◽  
Hind Mrabti ◽  
Hassan Errihani
Keyword(s):  
Bone Marrow ◽  
Rare Condition ◽  
Granulocytic Sarcoma ◽  
Myeloproliferative Disorders ◽  
Left Knee ◽  
Pathological Analysis ◽  
Extramedullary Tumor ◽  
End Of Treatment ◽  
Immature Myeloid Cells ◽  
Knee Mass

Granulocytic sarcoma (GS) is a rare extramedullary tumor composed of immature myeloid cells. It is usually associated with leukemia or other myeloproliferative disorders. It occurs very rarely without overt hematologic diseases. A 19-year-old man presented with left knee mass. Biopsy with pathological analysis showed lymphoma aspect. Immunostains yielded the diagnosis of GS with myeloperoxidase and CD43 positivity. There was no systemic manifestation of leukemia, and bone marrow biopsiy was negative for neoplastic infiltration. Chemotherapy by CHOP was efficient, and the patient remaind alive and healthy 40 months after the end of treatment. The case is discussed in the framework of the existing literature about the diagnosis, treatment, and prognosis of this very rare condition.

scholarly journals Granulocytic/myeloid sarcoma with trisomy 21 presented as an epididymal tumor: A case report and review of the literature

2020 ◽  
Vol 8 ◽  
pp. 2050313X2091922
Author(s):  
Masaki Murata ◽  
Kohei Inui ◽  
Oki Nagano ◽  
Go Hasegawa ◽  
Yohei Ikeda ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cytogenetic Analysis ◽  
Trisomy 21 ◽  
Bone Marrow Aspiration ◽  
Normal Karyotype ◽  
Bone Marrow Examination ◽  
Myeloid Sarcoma ◽  
Extramedullary Tumor ◽  
Immature Myeloid Cells ◽  
The Right

Myeloid sarcoma is an extramedullary tumor composed of immature myeloid cells and occurs in various extramedullary sites. We report a 48-year-old man diagnosed with myeloid sarcoma in the epididymis. He was admitted to our hospital due to a painless right intrascrotal mass. Magnetic resonance imaging showed a 30 mm tumor in the right epididymis, and we subsequently performed right high orchiectomy. The pathological diagnosis was myeloid sarcoma. Bone marrow aspiration and biopsy revealed no hematological disease, and cytogenetic analysis in the bone marrow showed normal karyotype. He was diagnosed with isolated myeloid sarcoma in the epididymis. Six months after the operation, myeloid sarcoma recurred in the para aorta and left sub-diaphragm. Bone marrow examination revealed myelodysplastic syndrome, and cytogenetic analysis showed 46, XY. We performed surgical resection of the recurrent mass, and cytogenetic analysis showed 47, XY, +21. He was diagnosed with recurrent MS with adult-onset trisomy 21. Although the effect of trisomy 21 on prognosis is unknown, the patient is currently undergoing systemic chemotherapy with maintained remission.

scholarly journals Granulocytic Sarcoma in a Nonleukemic Patient: Place of Radiotherapy and Systemic Therapies

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
C. Chargari ◽  
J. Jacob ◽  
O. Bauduceau ◽  
F. R. Ferrand ◽  
T. De Revel ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Peripheral Blood ◽  
Unusual Case ◽  
Granulocytic Sarcoma ◽  
Myeloproliferative Disorders ◽  
Therapeutic Strategies ◽  
Chronic Leukaemia ◽  
Acute Paraplegia ◽  
Spinal Epidural ◽  
Systemic Therapies

Granulocytic sarcoma is a rare extramedullary tumour, which most often occurs in the course of an acute or chronic leukaemia or myeloproliferative disorders. Rarely it is found before peripheral blood or bone marrow evidence of leukemia is present. We report an unusual case of acute paraplegia at first presentation of a spinal epidural granulocytic sarcoma without any haematological disorder. Therapeutic strategies are discussed in the light of the literature.

Granulocytic Sarcoma of the Small Intestine

2006 ◽  
Vol 130 (10) ◽  
pp. 1570-1574 ◽  
Author(s):  
Shane K. Kohl ◽  
Patricia Aoun
Keyword(s):  
Small Intestine ◽  
Correct Diagnosis ◽  
Granulocytic Sarcoma ◽  
Unknown Origin ◽  
Myelogenous Leukemia ◽  
Anatomic Site ◽  
Extramedullary Tumor ◽  
Acute Myelogenous ◽  
Immature Myeloid Cells ◽  
Appropriate Therapy

Abstract Granulocytic sarcoma is an extramedullary tumor of myeloblasts and/or immature myeloid cells, which can develop at any anatomic site and is often a forerunner to the development of acute myelogenous leukemia. Granulocytic sarcoma of the gastrointestinal tract most frequently involves the small intestine and most often presents with abdominal pain and obstruction. Pathologists must consider granulocytic sarcoma in any mass of unknown origin with a diffusely infiltrating population of tumor cells, as the diagnosis is often initially unrecognized, especially in nonleukemic patients. Multiple ancillary modalities are available to assist pathologists in making the correct diagnosis so that appropriate therapy can be initiated.

Granulocytic Sarcoma in Erythroleukemia (M6).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4629-4629
Author(s):  
Elham Abbasi ◽  
Martha P. Mims ◽  
Mark M. Udden
Keyword(s):  
Bone Marrow ◽  
Granulocytic Sarcoma ◽  
Myelogenous Leukemia ◽  
Positive Staining ◽  
Nasal Mass ◽  
Erythroid Precursors ◽  
Acute Myelogenous ◽  
History Of ◽  
Immature Myeloid Cells ◽  
Nasal Biopsy

Abstract Granulocytic Sarcomas are extramedullary tumors composed of immature myeloid cells, these tumors can be seen in myeloid malignancies such as chronic myelogenous leukemia, myelodysplastic syndrome and acute myelogenous leukemia. They can be seen at the time of diagnosis of the myeloid malignancy, prior to diagnosis, or after treatment as a first sign of relapse. We report here the case of a young woman who presented with a 6 month history of a slowly enlarging nasal mass. Biopsies of the lesion had been inconclusive until a CBC revealed abnormal blasts in the peripheral blood. Subsequently bone marrow biopsy revealed more than 59% erythroid precursors with a preponderance of immature erythroblasts and 33% myeloblast consistent with AML (M6). Reanalysis of the nasal biopsy demonstrated positive staining for CD68, Myeloperoxidase, Lysozyme, and CD117, but negative for CD34, suggestive of granulocytic sarcoma. The patient received induction chemotherapy with idarubicin and cytarabine and achieved bone marrow remission along with complete resolution of the nasal mass. To our knowledge this is the first report of a granulocytic sarcoma in association with AML M6.

Isolated granulocytic sarcoma: report of a case and review of the literature.

1986 ◽  
Vol 4 (6) ◽  
pp. 912-917 ◽  
Author(s):  
M Eshghabadi ◽  
A M Shojania ◽  
I Carr
Keyword(s):  
Combination Chemotherapy ◽  
Granulocytic Sarcoma ◽  
Myeloproliferative Disorders ◽  
Precursor Cells ◽  
Myelogenous Leukemia ◽  
Partial Mastectomy ◽  
Review Of The Literature ◽  
Initial Manifestation ◽  
Extramedullary Tumor ◽  
The Right

Granulocytic sarcoma (GS) is an extramedullary tumor composed of granulocytic precursor cells. The tumor usually develops during the course of myelogenous leukemia or myeloproliferative disorders and may represent the initial manifestation of leukemia. Rarely, GS is recognized as an isolated tumor without any evidence of leukemia. However, in such cases, leukemia generally develops within 1 to 2 years of the diagnosis of GS. We are reporting a case of a 45-year-old woman who was diagnosed as having an isolated GS of the right breast in August 1980. She was treated with a partial mastectomy followed by 1 year of combination chemotherapy as used in the cases of acute myeloblastic leukemia and has remained free of disease to the present time. That is, she has not developed leukemia or recurrence of GS for 64 months. Based on this experience and on the review of the literature, we recommend that all cases of GS be treated with combination chemotherapy as in cases of acute myeloblastic leukemias.

scholarly journals Nonleukemic Ureteral Granulocytic Sarcoma Presenting with Unilateral Urinary Obstruction and Hematuria

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Ömer Acar ◽  
Tarık Esen ◽  
Tülay Tecimer ◽  
Mustafa Çetiner ◽  
Önder Peker ◽  
...  
Keyword(s):  
Myeloid Leukemia ◽  
Transitional Cell ◽  
Granulocytic Sarcoma ◽  
Upper Urinary Tract ◽  
Lumbar Pain ◽  
Hematologic Disorder ◽  
Extramedullary Tumor ◽  
Chemotherapy Protocol ◽  
Immature Myeloid Cells ◽  
Segmental Ureterectomy

Granulocytic sarcoma is an extramedullary tumor which is composed of myeloblasts and immature myeloid cells. It usually occurs in association with acute myeloid leukemia and most commonly involves skin, soft tissue, lymph nodes, bone, and periosteum. We report a case of isolated ureteral granulocytic sarcoma without hematologic manifestations. Our patient presented with bloody urine and left-sided lumbar pain. Preoperative clinical and radiologic features raised the suspicion of an upper urinary tract transitional cell carcinoma, and he was scheduled for nephroureterectomy. However, perioperative pathologic feedback and the unusual endoscopic appearance of the tumor altered our surgical strategy towards segmental ureterectomy and ureteroneocystostomy. Eventual pathologic diagnosis was granulocytic sarcoma of the ureter. Postoperative workup failed to demonstrate any sign of an accompanying hematologic disorder. He started receiving the chemotherapy protocol of acute myeloblastic leukemia. To our knowledge, this is the first documented case of nonleukemic ureteral granulocytic sarcoma which came to attention due to urologic complaints.

Increased Response to Arachidonic Acid and U-46619 and Resistance to Inhibitory Prostaglandins in Patients with Chronic Myeloproliferative Disorders

1988 ◽  
Vol 59 (01) ◽  
pp. 073-076 ◽  
Author(s):  
Sergio Cortelazzo ◽  
Monica Galli ◽  
Donatella Castagna ◽  
Piera Viero ◽  
Giovanni de Gaetano ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Arachidonic Acid ◽  
Platelet Aggregation ◽  
Myeloproliferative Disorders ◽  
Bone Marrow Stem Cell ◽  
Healthy Controls ◽  
Aggregation Response ◽  
Thrombotic Complications ◽  
Cyclic Endoperoxide ◽  
Marrow Stem Cell

SummaryIn patients with myeloproliferative disorders (MPD) a group of related diseases of the bone marrow stem cell and recurrent haemorrhagic and/or thrombotic complications, the production of aggregating prostaglandins (PGs) may be normal or slightly reduced, while PGI2 production is normal. However, MPD platelet sensitivity to antiaggregatory PGs is still unknown.We studied the potency of PGD2, PGI2 and PGEi as inhibitors of platelet aggregation induced by threshold aggregating concentrations of arachidonic acid and U-46619-analogue of the cyclic endoperoxide PGH2 in 20 patients with MPD in comparison with healthy controls, with the aim of evaluating the sensitivity of MPD platelets to antiaggregatory PGs. In these patients platelet prostanoid metabolism was normal. However, the functional response of platelets to aggregating and antiaggregating prostanoids was shifted towards potentially increased platelet aggregation response. These findings could have a clinical relevance in view of the haemostatic and thrombotic complications so frequent in MPD.

Bone marrow necrosis and fat embolism syndrome: a near fatal complication in previously undiagnosed sickle beta + thalassaemia

2021 ◽  
Vol 14 (1) ◽  
pp. e238317
Author(s):  
Nibash Budhathoki ◽  
Sunita Timilsina ◽  
Bebu Ram ◽  
Douglas Marks
Keyword(s):  
Bone Marrow ◽  
Multiorgan Failure ◽  
Rare Condition ◽  
Altered Mental Status ◽  
Fat Embolism ◽  
Bone Marrow Necrosis ◽  
Embolism Syndrome ◽  
Hb S ◽  
High Index Of Suspicion ◽  
Specific Symptoms

Prevalence of haemoglobin sickle-β+ thalassaemia (Hb S/β+thal) is variable with geography ranging from 0.2% to 10% among sickle cell patients. Clinical presentation of Hb S/β+thal patients depends on HbA level, with milder disease often going undiagnosed. However, rarely these patients can present with a fulminant vaso-occlusive crisis (VOC). Given VOC can present with non-specific symptoms, the diagnosis and treatment is often delayed. Here, we present a patient who initially developed altered mental status, pancytopenia and multiorgan failure due a critical VOC resulting in bone marrow necrosis and fat embolism. Subsequent workup confirmed that our patient had Sickle-β+ thalassaemia, which had gone undiagnosed, despite subclinical evidence of haemolysis on routine lab work for years. Following diagnosis and initiation of RBC exchange, he improved significantly and was discharged home. High index of suspicion and bone marrow biopsy is vital for early diagnosis and management of this rare condition.

scholarly journals A review of current knowledge of myeloproliferative disorders in the horse

2021 ◽  
Vol 63 (1) ◽  
Author(s):  
Katy Satué ◽  
Juan Carlos Gardon ◽  
Ana Muñoz
Keyword(s):  
Bone Marrow ◽  
Myeloid Leukemia ◽  
Current Knowledge ◽  
Myeloproliferative Neoplasms ◽  
Myeloproliferative Disorders ◽  
World Health ◽  
Chronic Granulocytic Leukemia ◽  
Current State ◽  
Multiple Cell ◽  
Health Organization

AbstractMyeloid disorders are conditions being characterized by abnormal proliferation and development of myeloid lineage including granulocytes (neutrophils, eosinophils and basophils), monocytes, erythroids, and megakaryocytes precursor cells. Myeloid leukemia, based on clinical presentation and proliferative rate of neoplastic cells, is divided into acute (AML) and myeloproliferative neoplasms (MPN). The most commonly myeloid leukemia reported in horses are AML-M4 (myelomonocytic) and AML-M5 (monocytic). Isolated cases of AML-M6B (acute erythroid leukemia), and chronic granulocytic leukemia have also been reported. Additionally, bone marrow disorders with dysplastic alterations and ineffective hematopoiesis affecting single or multiple cell lineages or myelodysplastic diseases (MDS), have also been reported in horses. MDSs have increased myeloblasts numbers in blood or bone marrow, although less than 20%, which is the minimum level required for diagnosis of AML. This review performed a detailed description of the current state of knowlegde of the myeloproliferative disorders in horses following the criteria established by the World Health Organization.

scholarly journals Differential diagnosis of isolated myeloid sarcoma: a case report and review of the literature

2015 ◽  
Vol 7 (2) ◽  
Author(s):  
Patrick A. Hagen ◽  
Charanjeet Singh ◽  
Melissa Hart ◽  
Anne H. Blaes
Keyword(s):  
Bone Marrow ◽  
Marrow Transplantation ◽  
Bone Marrow Involvement ◽  
Lymph Node Biopsy ◽  
Myeloid Sarcoma ◽  
Unrelated Donor ◽  
Peripheral Cell ◽  
Bone Marrow Biopsies ◽  
Cell Counts ◽  
Extramedullary Tumor

Myeloid sarcoma (MS) is a rare disease entity identified as a variety of manifestations defined by the occurrence of extramedullary myeloid cell masses with or without bone marrow involvement. This case describes an unusual presentation of isolated MS in a 60-year-old otherwise healthy male, who initially presented to his primary care physician with vague abdominal pain. After extensive workup including three omental biopsies, umbilical core biopsy, and inguinal lymph node biopsy, he was ultimately diagnosed with isolated MS with extensive extramedullary tumor burden. Despite advanced extramedullary disease, peripheral cell counts were normal and bilateral bone marrow biopsies unremarkable with normal cellular lineages, morphology, and cytogenetics. The patient underwent induction chemotherapy and is now greater than 100 days post myeloablative unrelated donor marrow transplantation with no evidence of disease recurrence and 100% donor status with full chimerism. This case demonstrates that making a prompt diagnosis with rapid initiation of treatment in myeloid sarcoma can be challenging due to its varied clinical presentation, cytomorphology, cytochemistry, and cytogenetic overlap with other lymphoid malignancies. Once a diagnosis of MS has been made, moving quickly to induction therapy is important. Several studies have shown that improved overall survival is attained when MS is treated as acute myeloid leukemia and increased survival is noted for patients undergoing bone marrow transplantation. Further prospective studies are needed to elucidate the many remaining questions in regards to the natural history, prognosis, and optimal treatment strategies for this deadly disease.

Sign in / Sign up

Export Citation Format

Share Document